Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile?

Inflammatory Bowel Diseases

Volumn 14, Issue 2, 2008, Pages 224-235

  Kennedy, Erin D ^a   To, Theresa ^a   Steinhart, A Hillary ^a,b   Detsky, Allan ^a,b   Llewellyn Thomas, Hilary A ^c   McLeod, Robin S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Crohn's disease; Maintenance therapy; Minimal clinically important difference

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; FISH OIL; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OMEGA 3 FATTY ACID; PREDNISONE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ANKLE EDEMA; ARTHRALGIA; ARTICLE; BLOOD CELL COUNT; CAPILLARY RESISTANCE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; EMOTION; FEMALE; HAIR GROWTH; HAND PARESTHESIA; HUMAN; INTERVIEW; LOOSE FECES; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SIDE EFFECT; TASTE;

ADULT; AGED; AZATHIOPRINE; BUDESONIDE; CANADA; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DECISION SUPPORT TECHNIQUES; FEES, PHARMACEUTICAL; FEMALE; FISH OILS; FOCUS GROUPS; GASTROINTESTINAL AGENTS; HUMANS; MALE; MESALAMINE; METRONIDAZOLE; MIDDLE AGED; PATIENT SATISFACTION; POSTOPERATIVE CARE; RECURRENCE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 39649101932     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20300     Document Type: Article

References (38)

1. Deber RB. Physicians in health care management: 7. The patient-physician partnership: changing roles and the desire for information. CMAJ. 1994;151:171-176.
2. Deber RB. Physicians in health care management: 8. The patient-physician partnership: decision making, problem solving and the desire to participate. CMAJ. 1994;151:423-427.
3. Eddy DM. Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA. 1990;263:3077, 3081, 3084.
4. O'Connor AM, Fiset V, Degrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr. 1999;67-80.
5. O'Connor AM, Rostom A, Fiset V, et al. Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ. 1999;319:731-734.
6. Barry MJ, Cherkin DC, Chang Y, et al. A randomized trial of a multimedia shared decision-making program for men facing a treatment decision for benign prostatic hyperplasia. Dis Manag Clin Outcomes. 1997;1:5-14.
7. Fallowfield LJ, Hall A, Maguire GP, et al. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ. 1990;301:575-580.
8. Llewellyn-Thomas HA, Thiel EC, Clark RM. Patients versus surrogates: whose opinion counts on ethics review panels? Clin Res. 1989;37:501-505.
9. Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997;29:45-64.
10. Dales RE, O'Connor A, Hebert P, et al. Intubation and mechanical ventilation for COPD: development of an instrument to elicit patient preferences. Chest. 1999;116:792-800.
11. Llewellyn-Thomas H, Thiel E, Paterson M, et al. In the queue for coronary artery bypass grafting: patients' perceptions of risk and 'maximal acceptable waiting time.' J Health Serv Res Policy. 1999;4:65-72.
12. Llewellyn-Thomas HA, Arshinoff R, Bell M, et al. In the queue for total joint replacement: patients' perspectives on waiting times. Ontario Hip and Knee Replacement Project Team. J Eval Clin Pract. 1998;4:63-74.
13. Llewellyn-Thomas HA, Paterson JM, Carter JA, et al. Primary prevention drug therapy: can it meet patients' requirements for reduced risk? Med Decis Making. 2002;22:326-339.
14. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, et al. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997;15:3192-3200.
15. Percy ME, Llewellyn-Thomas H. Assessing preferences about the DNR order: does it depend on how you ask? Med Decis Making. 1995;15:209-216.
16. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997;15:330-340.
17. Brundage MD, Davidson JR, Mackillop WJ, et al. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making. 1998;18:256-267.
18. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
19. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
20. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, et al. Describing health states. Methodologic issues in obtaining values for health states. Med Care. 1984;22:543-552.
21. McNeil BJ, Pauker SG, Sox HC Jr, et al. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982;306:1259-1262.
22. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995;109:404-413.
23. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
24. Belluzzi A, Campieri M, Belloli C, et al. A new enteric coated preparation of omega-3-fatty-acids for preventing post-surgical recurrence in Crohn's disease. Gastroenterology. 1997;112:A930.
25. Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology. 1999;116:294-300.
26. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
27. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723-729.
28. Green SB, Salkind NJ, Akey TM. Using SPSS for Windows. Analyzing and understanding data. Upper Saddle River, NJ: Prentice-Hall; 1997.
29. Rosner B. Fundamentals of Biostatistics. 4th ed. Duxbury Press, division of Thomson Publishing Inc.; 1995.
30. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22:714-724.
31. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
32. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
33. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000;118:1018-1024.
34. Kennedy ED, To T, Detsky AS, et al. Azathioprine, methotrexate, remicade or surgery in chronic active Crohn's disease - what do patients prefer? Gastroenterology. 2001;120:A624.
35. Schreiber S, Hamling J, Wedel S, Nikolaus SN, Buhr HJ, Raedler A. Efficacy of patient education in chronic inflammatory bowel disease in a prospective controlled multicentre trial. Gastroenterology.. 1999;116:G3535.
36. Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000;12:13-18.
37. Hilsden RJ, Verhoef MJ, Best A, et al. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 2003;3:10.
38. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544.